The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Aug. 24, 7:09 PM

Slide #6. Eiger BioPharmaceuticals, Inc. Secondary Offering

Company: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
Date announced: 8/17/2016
Shares Offered: 1,250,000
Date of Pricing: 8/18/2016
Price Per Share: $16.00
Secondary Offering Details: Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Eiger intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be offered by Eiger. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 8/18- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,250,000 shares of its common stock at a price to the public of $16.00 per share, before underwriting discounts and commissions. All of the shares of common stock to be sold in the offering are to be sold by Eiger. The gross proceeds from the offering to Eiger are expected to be $20.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Eiger. In addition, Eiger has granted to the underwriters a 30-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Eiger BioPharmaceuticals is a clinical-stage biotechnology company focused on the development of cardiovascular gene therapy. Co.'s therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes gene therapies and small molecule compounds. Co. is evaluating its key product candidate, MYDICAR, in an international Phase 2b trial in patients with heart failure for reduced ejection fraction or HFrEF (also referred to as systolic heart failure), refers to as CUPID 2. Co. is also developing MYDICAR for additional indications, such as arteriovenous fistula, and for the treatment of patients with heart failure who are on a left-ventricular assist device.

EIGR SEC Filing Email Alerts Service

Open the EIGR Page at The Online Investor »

Company Name:  Eiger BioPharmaceuticals Inc
Website:  www.celladon.com
Sector:  Biotechnology
Number of ETFs Holding EIGR:  11
Total Market Value Held by ETFs:  $1.59M
Total Market Capitalization:  $119.00M
% of Market Cap. Held by ETFs:  1.33%
 

Open the EIGR Page at The Online Investor (in a new window) »

August 24, 2016    7:09 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
95th percentile
(ranked higher than approx. 95% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.